Correction: 1Q26 Interim Report
5 juni, 10:42
5 juni, 10:42
Modulight Corporation | Company Release | June 05, 2026 at 11:42:00 EEST
Modulight has identified an error in the presentation of certain balance sheet items in the financial statements released on 24-Apr-2026.
The error relates to the presentation of current liabilities. The amounts reported under accrued expenses and total current liabilities were incorrect.
The correct figures are as follows (EUR thousand):
Balance sheet item | Published figure | Correct figure |
Liabilities | ||
Non-current liabilities | ||
Loans from financial institutions | 988 | 988 |
Total non-current liabilities | 988 | 988 |
Current liabilities | ||
Loans from financial institutions | 1,502 | 1,502 |
Advances received | 53 | 53 |
Accounts payable | 285 | 285 |
Other liabilities | 164 | 164 |
Accrued expenses | 1,085 | 1,447 |
Total current liabilities | 1,949 | 3,451 |
Total liabilities | 4,439 | 4,439 |
The correction does not affect the Company's total liabilities, total assets, shareholders' equity, cash flow, operating result, profit for the financial year, or any previously reported key performance indicators. The correction concerns only the presentation of balance sheet items.
The corrected figures have been updated in the financial statements available on the Company's website.
The Company regrets the error.
For further information, please contact:
CEO Seppo Orsila, m. +358 40 830 4671
IR Ulla Haapanen, m. +358 40 830 4676
Email: ir@modulight.com
Certified adviser: Sisu Partners Oy, m. +358 40 555 4727
modulight.com
@modulight
Modulight in brief
Modulight Corporation is a life science company that designs and manufactures laser devices for the treatment of cancer and eye diseases. The company also manufactures products for other high value-add applications including flow cytometry, microscopy, semiconductor, quantum, and defense. The company’s products include medical devices, subsystems, software, cloud services, and specialized semiconductors. Modulight’s products are used worldwide by many Fortune 500 companies, pharmaceutical companies, and well-known cancer centers and universities. Modulight was founded in 2000 and is headquartered in Tampere, Finland.
Follow Modulight: modulight.com | X | LinkedIn | Facebook | YouTube | Instagram | #KillCancer
5 juni, 10:42
Modulight Corporation | Company Release | June 05, 2026 at 11:42:00 EEST
Modulight has identified an error in the presentation of certain balance sheet items in the financial statements released on 24-Apr-2026.
The error relates to the presentation of current liabilities. The amounts reported under accrued expenses and total current liabilities were incorrect.
The correct figures are as follows (EUR thousand):
Balance sheet item | Published figure | Correct figure |
Liabilities | ||
Non-current liabilities | ||
Loans from financial institutions | 988 | 988 |
Total non-current liabilities | 988 | 988 |
Current liabilities | ||
Loans from financial institutions | 1,502 | 1,502 |
Advances received | 53 | 53 |
Accounts payable | 285 | 285 |
Other liabilities | 164 | 164 |
Accrued expenses | 1,085 | 1,447 |
Total current liabilities | 1,949 | 3,451 |
Total liabilities | 4,439 | 4,439 |
The correction does not affect the Company's total liabilities, total assets, shareholders' equity, cash flow, operating result, profit for the financial year, or any previously reported key performance indicators. The correction concerns only the presentation of balance sheet items.
The corrected figures have been updated in the financial statements available on the Company's website.
The Company regrets the error.
For further information, please contact:
CEO Seppo Orsila, m. +358 40 830 4671
IR Ulla Haapanen, m. +358 40 830 4676
Email: ir@modulight.com
Certified adviser: Sisu Partners Oy, m. +358 40 555 4727
modulight.com
@modulight
Modulight in brief
Modulight Corporation is a life science company that designs and manufactures laser devices for the treatment of cancer and eye diseases. The company also manufactures products for other high value-add applications including flow cytometry, microscopy, semiconductor, quantum, and defense. The company’s products include medical devices, subsystems, software, cloud services, and specialized semiconductors. Modulight’s products are used worldwide by many Fortune 500 companies, pharmaceutical companies, and well-known cancer centers and universities. Modulight was founded in 2000 and is headquartered in Tampere, Finland.
Follow Modulight: modulight.com | X | LinkedIn | Facebook | YouTube | Instagram | #KillCancer

Rapporter i urval
Tech-rapporter
Börser i världen
Aktieanalys

Rapporter i urval
Tech-rapporter
Börser i världen
Aktieanalys
1 DAG %
Senast
OMX Stockholm 30
0,32%
(11:41)
AI
Idag, 10:59
Trump överväger AI-reglering
Aktiefonder
Idag, 10:57
Indexfonderna slår tillbaka
Troax
Idag, 09:42
Troax vinnare – Boliden tappar stort
Stockholmsbörsen
Idag, 09:39
Oregelbunden börsinledning
OMX Stockholm 30
1 DAG %
Senast
3 228,55